Duchesnay wins US FDA OK for morning sickness drug Diclegis
This article was originally published in Scrip
Executive Summary
Duchesnay won the US FDA's approval to market Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets as a therapy for nausea and vomiting related to pregnancy in women who do not respond to conservative management.